在胃肠道疾病中的肠道微生物群治疗
Hanif Ullah1, Safia Arbab2, Chengting Chang1
1Medicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, China.
Frontiers in cell and developmental biology
|March 13, 2025
概括
肠道微生物群对胃肠道健康有影响. 失衡 (失生症) 与疾病有关,但益生菌和FMT等微生物组疗法对治疗有希望.
科学领域:
- 微生物组研究的研究.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 人的肠道微生物群包括数万亿种对胃肠道健康至关重要的微生物.
- 微生物不平衡或失生症与炎症性肠病 (IBD),刺激性肠综合征 (IBS),乳病和结直肠癌有关.
- 肠道微生物群的相互作用影响宿主免疫力和肠-大脑轴,影响疾病的发病性.
研究的目的:
- 审查肠道微生物群在常见胃肠道疾病中的作用.
- 探索基于微生物组的新兴治疗策略.
- 讨论微生物干预的科学基础,临床有效性和挑战.
主要方法:
- 对肠道微生物群和胃肠道疾病研究的文献综述.
- 分析治疗方法,包括益生菌,益生菌,便微生物种移植 (FMT) 和饮食修改.
- 检查微生物组调节的科学证据和临床结果.
主要成果:
- 消化不良是各种胃肠道疾病的发展和进展的一个重要因素.
- 针对微生物组的疗法显示出恢复微生物平衡和缓解疾病症状的潜力.
- 像益生菌,益生菌和FMT这样的干预措施提供了新的治疗途径.
结论:
- 基于微生物组的治疗方法在治疗胃肠道疾病方面是一个有前途的前沿.
- 这些疗法为传统治疗提供了个性化和替代的选择.
- 持续的研究对于优化微生物组干预措施以改善患者结果至关重要.
相关概念视频
Bacterial Flora of the Large Intestine
370
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
370
What is Monogastric Digestion?
70.4K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
70.4K
Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
106
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
106
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
290
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
Drugs for Treatment of Diarrhea-Predominant IBS
133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133


